SEC Company Response from Mereo BioPharma Group plc (MREO) (CIK 0001719714) (MREO) — Mar 18, 2020
Mereo BioPharma Group plc (MREO) (CIK 0001719714)
Date: March 18, 2020 · CIK: 0001719714 · Accession: 0001193125-20-076926
AI Filing Summary & Sentiment
File numbers found in text: 333-236497
Letter
Mereo BioPharma Group plc
Fourth Floor
One Cavendish Place
London W1G 0QF
United Kingdom
March 18, 2020
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Mereo BioPharma Group plc
Registration Statement on Form F-1
File No. 333-236497
VIA EDGAR
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mereo BioPharma Group plc (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-236497) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 9:00 a.m., Eastern Time, on March 19, 2020 or as soon thereafter as may be practicable.
The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Mayer Brown LLP, by calling David S. Bakst at (212) 506-2551. The Company hereby authorizes Mr. Bakst to orally modify or withdraw this request for acceleration.
Very truly yours,
MEREO BIOPHARMA GROUP PLC
Show Raw Text
CORRESP 1 filename1.htm CORRESP Mereo BioPharma Group plc Fourth Floor One Cavendish Place London W1G 0QF United Kingdom March 18, 2020 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Mereo BioPharma Group plc Registration Statement on Form F-1 File No. 333-236497 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Mereo BioPharma Group plc (the “Registrant”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-236497) of the Registrant (the “Registration Statement”) be accelerated so that it will be declared effective at 9:00 a.m., Eastern Time, on March 19, 2020 or as soon thereafter as may be practicable. The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Mayer Brown LLP, by calling David S. Bakst at (212) 506-2551. The Company hereby authorizes Mr. Bakst to orally modify or withdraw this request for acceleration. Very truly yours, MEREO BIOPHARMA GROUP PLC By: /s/ Denise Scots-Knight Name: Denise Scots-Knight Title: Chief Executive Officer Cc: David S. Bakst Mayer Brown LLP Richard Jones Charles Sermon Mereo BioPharma Group plc